Annual report pursuant to Section 13 and 15(d)

Segment Information (Tables)

Segment Information (Tables)

12 Months Ended

Jun. 30, 2014

Financial Information Relating to Operating Segments

Following is financial information relating to the operating segments (in thousands):


	Year Ended June 30,
	2014			2013			2012
External sales
Biotechnology	$	300,578		$	288,156		$	293,274
Clinical Controls		57,185			22,419			21,286

Consolidated net sales	$	357,763		$	310,575		$	314,560

Earnings before taxes
Biotechnology	$	159,220		$	156,910		$	162,763
Clinical Controls		10,643			8,746			8,002

Segment earnings before taxes		169,863			165,656			170,765
Corporate		(8,471	)		(4,994	)		(8,570	)

Consolidated earnings before taxes	$	161,392		$	160,662		$	162,195

Goodwill
Biotechnology	$	95,124		$	84,336		$	85,682
Clinical Controls		56,349			0			0

Consolidated goodwill	$	151,473		$	84,336		$	85,682

Intangible assets, net
Biotechnology	$	53,778		$	40,552		$	46,476
Clinical Controls		54,998			0			0

Consolidated intangible assets, net	$	108,776		$	40,552		$	46,476


	Year Ended June 30,
	2014		2013		2012
Assets
Biotechnology	$	685,302	$	580,085	$	529,392
Clinical Controls		55,615		24,887		22,135

Segment assets		740,917		604,972		551,527
Corporate cash and available- for- sale investments		60,142		108,504		112,443
Corporate property and equipment		60,350		61,296		51,587
Corporate, other		1,082		3,326		3,767

Consolidated assets	$	862,491	$	778,098	$	719,324

Depreciation and amortization
Biotechnology	$	10,879	$	10,781	$	10,920
Clinical Controls		7,205		389		411

Segment depreciation and amortization		18,084		11,170		11,331
Corporate		1,091		1,151		1,136

Consolidated depreciation and amortization	$	19,175	$	12,321	$	12,467

Capital purchases
Biotechnology	$	4,157	$	3,248	$	4,021
Clinical Controls		5,687		6,914		597

Segment capital purchases		9,844		10,162		4,618
Corporate		3,977		12,292		1,399

Consolidated capital purchases	$	13,821	$	22,454	$	6,017

Financial Information Relating to Geographic Areas

Following is financial information relating to geographic areas (in thousands):


	Year Ended June 30,
	2014		2013		2012
External sales
United States	$	190,359	$	164,308	$	172,310
Europe		97,157		88,297		90,142
China		18,878		14,106		11,378
Other Asia		32,704		28,608		25,988
Rest of world		18,665		15,256		14,742

Total external sales	$	357,763	$	310,575	$	314,560

Long-lived assets
United States	$	109,790	$	103,541	$	87,968
Europe		8,340		7,129		7,528
China		678		117		141

Total long-lived assets	$	118,808	$	110,787	$	95,637

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details